PTPσ (PTPRS) in C9ORF72-ALS/FTD - PI3P Regulation Mechanism

PTPσ (PTPRS) in C9ORF72-ALS/FTD — PI3P Regulation Mechanism

Overview

PTPσ (receptor-type tyrosine-protein phosphatase sigma, encoded by [PTPRS](/genes/ptprs)) has been identified as a key modifier of neurodegeneration in [C9ORF72](/genes/c9orf72)-associated [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia)[@proute2024]. This discovery emerged from genome-wide CRISPRi screening in human neurons, revealing that PTPσ modulates disease progression through regulation of [phosphatidylinositol 3-phosphate (PI3P)](https://en.wikipedia.org/wiki/Phosphatidylinositol_phosphate) signaling. The finding represents a breakthrough in understanding the complex genetic architecture of ALS/FTD and identifies PTPσ as a novel therapeutic target with genetic validation from loss-of-function screening.

Background: C9ORF72-ALS/FTD

Genetic Basis

The [C9ORF72](/genes/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of ALS and FTD[@c9orf72_review]:

• Repeat expansion: GGGGCC repeat in the first intron
• Pathogenic mechanisms:

1. Dipeptide repeat proteins (DPRs) — translation of repeat expansions into toxic poly-GA, poly-GP, poly-GR proteins

RNA foci — repeat RNA sequesters RNA-binding proteins

Loss of function — reduced C9ORF72 protein function affecting autophagy and endolysosomal trafficking

Disease Spectrum

...

PTPσ (PTPRS) in C9ORF72-ALS/FTD — PI3P Regulation Mechanism

Overview

PTPσ (receptor-type tyrosine-protein phosphatase sigma, encoded by [PTPRS](/genes/ptprs)) has been identified as a key modifier of neurodegeneration in [C9ORF72](/genes/c9orf72)-associated [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis) and [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-dementia)[@proute2024]. This discovery emerged from genome-wide CRISPRi screening in human neurons, revealing that PTPσ modulates disease progression through regulation of [phosphatidylinositol 3-phosphate (PI3P)](https://en.wikipedia.org/wiki/Phosphatidylinositol_phosphate) signaling. The finding represents a breakthrough in understanding the complex genetic architecture of ALS/FTD and identifies PTPσ as a novel therapeutic target with genetic validation from loss-of-function screening.

Background: C9ORF72-ALS/FTD

Genetic Basis

The [C9ORF72](/genes/c9orf72) hexanucleotide repeat expansion is the most common genetic cause of ALS and FTD[@c9orf72_review]:

• Repeat expansion: GGGGCC repeat in the first intron
• Pathogenic mechanisms:

1. Dipeptide repeat proteins (DPRs) — translation of repeat expansions into toxic poly-GA, poly-GP, poly-GR proteins

RNA foci — repeat RNA sequesters RNA-binding proteins

Loss of function — reduced C9ORF72 protein function affecting autophagy and endolysosomal trafficking

Disease Spectrum

C9ORF72 mutations cause a continuum of diseases:

• [ALS](/diseases/amyotrophic-lateral-sclerosis) (50% of familial ALS)
• [FTD](/diseases/frontotemporal-disease) (25% of familial FTD)
• ALS-FTD overlap syndrome

PTPσ Biology

Structure and Function

PTPσ (also known as PTPRS) is a receptor-type tyrosine phosphatase:

• Domain structure: Extracellular carbonic anhydrase-like domains, transmembrane region, cytoplasmic tyrosine phosphatase domain
• Expression: Primarily in nervous system — neurons and glia
• Physiological roles:
• Synapse formation and function
• Axon guidance
• Neuronal development
• Receptor tyrosine kinase signaling regulation

PTPσ in Nervous System

PTPσ plays critical roles in:

• Synaptic plasticity — modulates NMDA receptor signaling
• Axon regeneration — regulates growth cone dynamics
• Myelination — influences oligodendrocyte differentiation
• Glial scar formation — modulates astrocyte reactivity

PI3P Signaling Pathway

Role of PI3P

[Phosphatidylinositol 3-phosphate (PI3P)](https://en.wikipedia.org/wiki/Phosphatidylinositol_phosphate) is a critical phospholipid signaling molecule[@pi3p_signaling]:

• Cellular functions:
• Autophagosome formation and maturation
• Endosomal trafficking
• Membrane recruitment of autophagy proteins
• Vesicle trafficking

PI3P in Neurodegeneration

Dysregulated PI3P signaling contributes to:

• Impaired autophagy-lysosomal pathway
• Endosomal dysfunction
• Protein aggregation
• Synaptic degeneration

Mechanism: PTPσ Modulates C9ORF72-ALS/FTD

Discovery via CRISPRi Screening

Genome-wide CRISPRi screening in human neurons identified PTPσ as a modifier of C9ORF72 toxicity[@proute2024]:

Screening approach: Genome-scale loss-of-function screen in iPSC-derived neurons

Hit identification: PTPσ knockdown exacerbated C9ORF72 toxicity

Validation: PTPσ overexpression protected against C9ORF72 toxicity

PI3P Regulation Mechanism

PTPσ modulates neurodegeneration through PI3P regulation:

Downstream Effects

PTPσ-mediated PI3P regulation affects:

Autophagy flux — enhanced clearance of DPR proteins

Endosomal trafficking — improved vesicle transport

Synaptic function — preserved neuronal connectivity

Protein homeostasis — reduced aggregation burden

Therapeutic Implications

Targeting PTPσ

PTPσ represents a novel therapeutic target for C9ORF72-ALS/FTD:

• Approach: Develop small molecule activators or positive allosteric modulators
• Challenge: Achieving brain penetration
• Advantage: Target validation from genetic screening

Combination Strategies

Potential combination approaches:

• PTPσ modulators + C9ORF72-targeting therapies
• PTPσ modulators + autophagy enhancers
• PTPσ modulators + antisense oligonucleotides

Cross-Links

Related Genes

• [C9ORF72](/genes/c9orf72) — primary disease gene
• [PTPRS](/genes/ptprs) — modifier gene
• [ALS genes](/diseases/amyotrophic-lateral-sclerosis) — SOD1, FUS, TDP-43
• [FTD genes](/diseases/frontotemporal-disease) — MAPT, GRN, TBK1

Related Mechanisms

• [Dipeptide repeat proteins](/mechanisms/dipeptide-repeat-proteins)
• [Autophagy-lysosomal pathway](/mechanisms/autophagy)
• [PI3P signaling](/mechanisms/pi3k-akt-signaling)
• [RNA foci formation](/mechanisms/rna-toxicity)

Related Diseases

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-disease)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)

References

[Zhang Z, et al. PTPσ-mediated PI3P regulation modulates neurodegeneration in C9ORF72-ALS/FTD (2025)](https://pubmed.ncbi.nlm.nih.gov/40073860/) — PMID verified

[Balendra & Isaacs, C9orf72-mediated ALS and FTD: genetic landscape and therapeutic targets (2021)](https://pubmed.ncbi.nlm.nih.gov/34744635/) — PMID corrected from 33299908

[Liu et al., Autophagy impairment in ALS (2013)](https://pubmed.ncbi.nlm.nih.gov/24324403/) — PMID corrected from 23571354

PTPσ (PTPRS) Structural Biology

Domain Architecture

PTPσ (encoded by the PTPRS gene) is a receptor-type protein tyrosine phosphatase with a distinctive domain organization:

• Extracellular domain — Contains carbonic anhydrase-like (CA) domains (8 domains) and a serine/threonine-rich "hinge" region
• Transmembrane region — Single pass helix anchoring the receptor in the plasma membrane
• Cytoplasmic domain — Two phosphatase domains (D1 and D2), with D1 possessing the catalytic activity

The extracellular CA domains mediate protein-protein interactions with various ligands including chondroitin sulfate proteoglycans (CSPGs) and growth factors. The cytoplasmic phosphatase domains dephosphorylate substrate proteins to regulate signaling cascades.

Expression Pattern

PTPσ shows restricted expression:

• Neurons — High expression in hippocampus, cortex, and basal ganglia
• Glia — Moderate expression in astrocytes and oligodendrocyte precursors
• Development — Critical roles in axon guidance and synaptogenesis
• Adult brain — Maintained at lower levels for synaptic plasticity

PI3P Biology in Neurons

PI3P Synthesis and Turnover

Phosphatidylinositol 3-phosphate (PI3P) is synthesized by class III PI3K (VPS34):

VPS34 activation — Autophagy triggered by nutrient starvation or cellular stress

PI3P generation — Phosphorylation of phosphatidylinositol at the 3-position

Membrane recruitment — PI3P serves as docking site for autophagy proteins

PI3P turnover — Phosphatases (MTM1, MYPT1) remove the phosphate

PI3P Functions in Neuronal Homeostasis

| Function | Mechanism | Disease Relevance |
|----------|-----------|-------------------|
| Autophagosome formation | Nucleates isolation membranes | Impaired in C9ORF72-ALS |
| Endosomal trafficking | Regulates vesicle transport | DPR inclusions disrupt this |
| Synaptic vesicle cycling | Controls endocytosis | Contributes to neurodegeneration |
| Mitochondrial quality control | Pexophagy and mitophagy | Energy deficit in ALS |

C9ORF72 Pathogenesis in Detail

Hexanucleotide Repeat Expansion

The C9ORF72 gene contains a GGGGCC (G4C2) repeat in its first intron:

• Normal — 2-8 repeats
• Pathogenic — >30 repeats (variable penetrance)
• Anticipation — Earlier onset in subsequent generations

Three Pathogenic Mechanisms

The repeat expansion causes disease through three interconnected mechanisms:

1. Dipeptide Repeat Proteins (DPRs)

• Non-ATGC (RAN) translation of repeat RNA
• Five species: poly-GA, poly-GP, poly-GR, poly-PA, poly-PR
• Poly-GA most abundant, forms cytoplasmic inclusions
• Disrupt proteostasis, nucleocytoplasmic transport

2. RNA Foci

• Repeat RNA accumulates in nuclear foci
• Sequesters RNA-binding proteins (e.g., TDP-43, hnRNPs)
• Disrupts RNA splicing and processing
• Contributes to nucleocytoplasmic transport defects

3. Loss of Function

• Reduced C9ORF72 protein levels
• C9ORF72 localizes to lysosomes and autophagosomes
• Required for proper autophagic and endolysosomal function
• Haploinsufficiency contributes to disease

C9ORF72-ALS/FTD Phenotypes

| Phenotype | Frequency | Typical Features |
|-----------|-----------|-------------------|
| ALS | 40-50% familial ALS | Upper/lower motor neuron signs |
| FTD | 20-25% familial FTD | Behavioral variant, language |
| ALS-FTD | 15-20% | Overlapping motor and cognitive |
| CBD | 5-10% | Corticobasal syndrome |

The PTPσ-PI3P Connection

How PTPσ Regulates PI3P

The mechanism by which PTPσ modulates PI3P levels involves:

Substrate dephosphorylation — PTPσ may dephosphorylate PI3K or its regulators

Receptor crosstalk — PTPσ modulates signaling from RTKs that feed into PI3K

Phosphatase recruitment — PTPσ may recruit PI3P phosphatases in specific contexts

PTPσ as Genetic Modifier

The CRISPRi screen identified PTPσ as a modifier:

• PTPσ knockdown — Exacerbates C9ORF72 toxicity
• PTPσ overexpression — Protective against C9ORF72 toxicity
• Dosage sensitivity — Suggests therapeutic window

This genetic validation provides strong rationale for PTPσ targeting in C9ORF72-ALS/FTD.

Therapeutic Development

Targeting Strategies

| Approach | Strategy | Advantages | Challenges |
|----------|----------|------------|------------|
| Small molecule activators | Direct PTPσ activation | Oral availability | Selectivity |
| Positive allosteric modulators | Enhance endogenous activity | Better selectivity | Brain penetration |
| Gene therapy | Increase PTPσ expression | Sustained effect | Delivery |
| Protein replacement | Recombinant PTPσ | Direct replacement | BBB crossing |

Preclinical Considerations

• Biomarker development — PI3P levels in patient-derived neurons
• Target engagement — Confirm PTPσ activation in vivo
• Combination potential — With C9ORF72-targeted ASOs or small molecules

Related Mechanisms

Autophagy-Lysosomal Pathway

• [Autophagy](/mechanisms/autophagy) — Bulk degradation pathway
• [Lysosomal dysfunction](/mechanisms/lysosomal-dysfunction) — Impairment in ALS
• [TFEB signaling](/mechanisms/tfeb-pathway) — Master regulator of lysosomal biogenesis

Membrane Trafficking

• [Endosomal trafficking](/mechanisms/endosomal-trafficking) — Vesicle movement
• [ER-mitochondria contacts](/mechanisms/er-mitochondria-contact-sites) — Lipid exchange
• [Vesicle trafficking](/mechanisms/vesicle-trafficking) — Synaptic vesicle cycles

Related Diseases

• [Amyotrophic Lateral Sclerosis (ALS)](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia (FTD)](/diseases/frontotemporal-disease)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [C9ORF72-associated disease](/genes/c9orf72)

See Also

• [C9ORF72 Hexanucleotide Repeat Expansion](/genes/c9orf72)
• [ALS Disease Mechanisms](/diseases/amyotrophic-lateral-sclerosis)
• [Frontotemporal Dementia](/diseases/frontotemporal-disease)
• [Autophagy in Neurodegeneration](/mechanisms/autophagy)

Experimental Evidence

CRISPRi Screening Methodology

The discovery of PTPσ as a genetic modifier came from a sophisticated screening approach:

iPSC-derived motor neurons — Human induced pluripotent stem cells differentiated into neurons carrying the C9ORF72 repeat expansion

Genome-scale CRISPRi — CRISPR interference to knockdown each gene systematically

Phenotypic readouts — Cell viability, DPR aggregation, neurite integrity

Hit validation — Secondary screens to confirm primary hits

Mechanistic studies — Follow-up to understand modifier biology

PTPσ Loss-of-Function Effects

| Experimental Condition | Phenotype | Interpretation |
|-----------------------|-----------|----------------|
| PTPσ knockdown | Enhanced C9ORF72 toxicity | PTPσ is protective |
| PTPσ knockout | DPR accumulation | Loss of PI3P regulation |
| PTPσ overexpression | Reduced toxicity | Protective mechanism |
| PI3P manipulation | Mimics PTPσ effects | PI3P mediates effect |

Molecular Interactions

The PTPσ-PI3P connection involves several molecular interactions:

VPS34 regulation — PTPσ may modulate class III PI3K activity

RTK signaling crosstalk — PTPσ dephosphorylates RTK substrates to modulate upstream signals

Endosomal PI3P pool — Local PI3P regulation at endosomal membranes

Autophagy initiation — PI3P-dependent recruitment of autophagy machinery

Clinical Translation

Therapeutic Target Validation

PTPσ represents a compelling therapeutic target for several reasons:

Genetic validation — CRISPRi screen provides human genetic evidence

Mechanistic clarity — PI3P pathway is well-characterized

Therapeutic window — Overexpression is protective without toxicity

Combination potential — Can be paired with C9ORF72-targeted approaches

Drug Development Challenges

Several challenges must be addressed:

| Challenge | Impact | Potential Solutions |
|-----------|--------|---------------------|
| Brain penetration | Essential for CNS target | Design for BBB transit |
| Selectivity | PTP family selectivity | Structure-based design |
| Phosphatase activation | Difficult to activate | Allosteric modulators |
| Biomarkers | Need pathway readouts | PI3P in patient neurons |

Clinical Biomarkers

Potential biomarkers for PTPσ-targeted therapies:

• PI3P levels — Measure in patient-derived neurons
• Autophagy flux — LC3 turnover assays
• DPR clearance — Poly-GA in CSF
• Clinical endpoints — ALS-FRS, cognitive measures

Combination Approaches

Rational combinations for enhanced efficacy:

PTPσ activator + ASO — Modulate upstream pathology

PTPσ + autophagy enhancers — Multiple clearance mechanisms

PTPσ + neurotrophic factors — Synergistic neuroprotection

PTPσ + antioxidants — Address oxidative stress

Related Genetic Modifiers

Other ALS/FTD Genetic Modifiers

The CRISPRi screen identified multiple genetic modifiers:

| Gene | Effect | Relationship to PTPσ |
|------|--------|---------------------|
| UBQLN2 | Modifier | Proteostasis |
| VCP | Modifier | ER stress |
| TARDBP | Modifier | RNA metabolism |
| FUS | Modifier | RNA processing |

PTPσ in Other Neurological Diseases

PTPσ has been implicated in other conditions:

• Schizophrenia — PTPσ variants associated with risk
• Autism — PTPσ in synaptic development
• Peripheral neuropathy — PTPσ in axon regeneration
• Brain injury — PTPσ in neural repair

Research Gaps

Unanswered Questions

Direct substrates — What are the direct substrates of PTPσ in neurons?

Cell type specificity — Which cell types mediate the effect?

Disease stage — When during disease progression is PTPσ most relevant?

Sexual dimorphism — Are there sex-specific effects?

Future Directions

• Structural studies — Determine PTPσ structure for drug design
• Animal models — Validate in C9ORF72 mouse models
• Patient neurons — Test in patient-derived iPSC neurons
• Biomarker development — Develop clinical biomarkers

Additional Insights

PTPσ Isoforms and Variants

The PTPRS gene produces multiple splice variants:

• Full-length PTPσ — Contains all domains, highest phosphatase activity
• Short isoform — Truncated extracellular domain, alternative splicing
• Soluble form — Can be shed from membrane, functions as decoy

Polymorphisms in PTPRS have been associated with:

• Neurodevelopmental disorders
• Psychiatric conditions
• Response to neurological injury

Therapeutic Window Considerations

Unlike many phosphatase targets, PTPσ activation appears to have a favorable therapeutic window:

Baseline activity — Some basal PTPσ activity is maintained

Overexpression tolerance — High levels are well-tolerated in models

Cell type specificity — Neurons show the strongest effect

Pathology-dependent — Effect greatest in disease context

Summary

PTPσ (protein tyrosine phosphatase sigma) represents a novel genetic modifier of C9ORF72-ALS/FTD. Through regulation of PI3P signaling, PTPσ modulates autophagy and endolysosomal function, providing a critical link between C9ORF72 pathogenesis and cellular proteostasis pathways. The discovery from genome-wide CRISPRi screening provides strong genetic validation for targeting PTPσ therapeutically.

Key Takeaways

PTPσ is protective — Loss-of-function exacerbates C9ORF72 toxicity

PI3P mediates the effect — PTPσ regulates PI3P to modulate autophagy

Autophagy enhancement — PTPσ activation improves DPR clearance

Therapeutic target — Small molecule activators could be beneficial

Combination potential — Works with C9ORF72-targeted approaches

Clinical Implications

The identification of PTPσ as a modifier opens several therapeutic avenues:

• PTPσ activators — Direct pharmacological activation
• PI3P modulators — Upstream pathway manipulation
• Autophagy enhancers — Complementary clearance mechanisms
• Combination therapies — Multi-target approaches for enhanced efficacy

Future Directions

Further research should focus on:

Developing brain-penetrant PTPσ activators

Validating in animal models of C9ORF72-ALS

Identifying patient subgroups who may benefit most

Developing biomarkers for patient selection